Keywords: idec, results, driven, rituxan, pharmaceuticals, says, revenues
IDEC results driven by Rituxan
Article | 29 April 2002
IDEC Pharmaceuticals says that revenues for the first quarter of 2002were $79.7 million, representing a 41.1% rise compared to the like, year-earlier ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
